Better Therapeutics, Inc.

BTTX

US08773T1043

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:53:14 2024-04-26 pm EDT			5-day change	1st Jan Change
0.01 ^USD	+11.11%		+61.29%	-94.87%

Mar. 21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
Mar. 20	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Better Therapeutics, Inc. announced that it has received $2.115287 million in funding

August 10, 2023

On August 11, 2023, Better Therapeutics, Inc. closed the transaction. The transaction included participation from 10 investors. The company has paid sales commissions of $126,900 in the transaction.

Latest news about Better Therapeutics, Inc.

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	Mar. 21	CI
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	Mar. 19	CI
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index	Mar. 14	CI
Sector Update: Health Care Stocks Lower Thursday Afternoon	Mar. 14	MT
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	Mar. 14	MT
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	Feb. 20	MT
Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	Feb. 20	DJ
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	Feb. 20	CI
Better Therapeutics, Inc. announced that it has received $0.25 million in funding	Jan. 22	CI
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	Jan. 17	CI
Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding	Jan. 04	CI
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	Jan. 03	CI
Better Therapeutics Seeks FDA Breakthrough Device Designation for Prescription Digital Therapeutics Targeting Liver Diseases	Jan. 02	MT
Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	Jan. 02	CI
Better Therapeutics, Inc. Enters into Second Amendment to Loan Agreement with Hercules Capital, Inc	Nov. 30	CI
Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023	Nov. 20	CI
Transcript : Better Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Better Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
SHARES OF BETTER THERAPEUTICS UP 24.4% AFTER CO ANNOUNCES LAUNCH…	23-10-16	RE
Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes	23-10-11	CI
Better Therapeutics Says Study of Novel Cognitive Behavioral Therapy Platform Meets Endpoints	23-10-05	MT
Better Therapeutics Completes Enrollment in Study Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	23-09-28	MT
Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	23-09-28	CI
Better Therapeutics, Inc. announced that it has received $2.115287 million in funding	23-08-10	CI
Transcript : Better Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09

Chart Better Therapeutics, Inc.

Duration

Period

More charts

Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.01 USD

Average target price

1.5 USD

Spread / Average Target

+14,900.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BETTER THERAPEUTICS, INC.	-94.87%	545K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research